SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " M.D " 122 found 🔀 AI-powered Shuffle
Johns Hopkins Researchers’ Cancer Cell Mapping Technology Chosen for Anthropic AI for Science Project
Johns Hopkins University astrophysicist Alexander Szalay, Ph.D., and Johns Hopkins Medicine Department of Dermatology and Sidney Kimmel Comprehensive Cancer Center pathologist Janis Taube, M.D., M.Sc., were chosen for a research project in Anthropic's AI for Science program. They were selected for their pioneering AstroPath technology, which combines astronomy, pathology and artificial intelligence (AI) to create detailed maps of tumors, revealing how cancer cells interact with surrounding cells
Erin Gillaspie, M.D. M.P.H., Joins Baptist Health Herbert Wertheim Cancer Institute as Chief of Thoracic Surgery - Florida Hospital News and Healthcare Report
October 28, 2026 – Erin Gillaspie, M.D., M.P.H., has joined Baptist Health Herbert Wertheim Cancer Institute and Baptist Health Cancer Care as chief of thoracic surgery. Dr. Gillaspie is dual […]
Vir Biotechnology appoints Suzanne Topalian to board and Science and Technology Committee
Vir Biotechnology appointed Suzanne Topalian, M.D., to its board and Science and Technology Committee, effective October 27, 2026.Original SEC Filing: Vir Biotechnology, Inc. [ VIR ] - 8-K - Oct. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important inform…
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. The open-label Krascendo 1 trial enrolled 338 people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Patients who had already received a KRAS G12C inhibitor or pan-KRAS/RAS inhibitor were excluded from the trial. Participants received either divarasib once daily, Lumakras once daily or Krazati twice daily. Roche announced back in July that divarasib had demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS), meeting the trial’s primary and key secondary endpoints. But the Swiss pharma had been holding back the detailed data until now. At the European Society for Medical Oncology (ESMO) Congress in Madrid, Roche revealed that median OS for the 167 patients who received divarasib was 17.7 months, compared to 12 months for the 171 patients who received Lumakras or Krazati. The benefit was similarly clear when it came to median PFS, which stood at 9.8 months versus 5.7 months, respectively. A total of 44% of patients receiving divarasib were alive without disease progression at one year, compared to 24% of the control group, according to Roche’s presentation. It was a similar story for the objective response rate, which came in at 58% for divarasib versus 32% for the control group, while median duration of response was 11.9 months versus 6.9 months. Stefan Frings, M.D., Ph.D., deputy chief medical officer at Roche Pharma, told Fierce that the data made for a “very comprehensive, strong package, which should be convincing to health authorities.” “It’s an important advance for patients with lung cancer,” Frings said in an interview at a Madrid hotel during the conference. “It's a second-line setting, and patients who receive divarasib benefit compared to the current first-generation KRAS G12C inhibitors by having far longer overall survival,” he continued. “They live longer. They have better progression-free survival, better response rates, and with a safety profile which is—if [anything]—even better,” he said. According to Roche, 4.8% of patients receiving divarasib discontinued treatment due to treatment-related adverse events, compared to 11.7% in the control group. Serious treatment-related adverse events were also less common with divarasib, at 7.8% versus 15.2%. Roche’s confidence in divarasib had been building even before this phase 3 success. The candidate had already shown better potency and selectivity than the incumbent KRAS G12C inhibitors Krazati and Lumakras in preclinical tests. After cross-trial comparisons suggested that the edge translated into better clinical outcomes, Roche axed a study comparing divarasib to the chemotherapy docetaxel and went toe-to-toe with Lumakras and Krazati. “We designed the drug on purpose with higher potency and better selectivity,” Frings explained. “So, based on preclinical models, we clearly knew it would be superior to the first generation.” “It’s honestly not so frequent that pharma companies go head-to-head,” he added. “But if you want to make a point, if you want to convince payers, prescribers and patients … then a head-to-head win is rather rewarding.” While Amgen and BMS reached the regulatory finish line first for KRAS G12C-mutated, locally advanced or metastatic NSCLC in 2021 and 2022, respectively, they have struggled to capitalize on their head start. Krazati brought in $55 million for BMS in the second quarter, while Lumakras delivered $111 million to Amgen. For its part, Roche is aiming for peak divarasib sales of 1 billion to 2 billion Swiss francs ($1.2 billion to $2.5 billion), according to Frings. The Big Pharma is currently recruiting patients into a phase 3 trial comparing divarasib plus Keytruda against Keytruda plus chemotherapy in previously untreated advanced or metastatic nonsquamous KRAS G12C-mutated NSCLC. Roche has previously suggested that sales in metastatic disease would account for most of the forecast. Frings was tight-lipped on the exact timeline for a regulatory filing but said the Swiss pharma is “certainly keen to get this to as many patients as possible around the world.” Roche has more RAS drugs coming up behind divarasib. The pharma has already launched phase 1 trials of a pan-RAS inhibitor called RG6505 and a KRAS G12D inhibitor dubbed RG6620 in solid tumors. Roche’s partner Chugai Pharmaceutical is also testing a pan-KRAS inhibitor called AUBE00. Roche has made a “deliberate effort” to test a range of RAS drugs, Frings said. “If you have many rare mutations and you are scrambling to find sufficient patients, a pan-RAS inhibitor makes a lot of sense,” he explained.
Popular olive oil shot trend has Americans chasing health benefits as doctor questions the hype
Should you take olive oil shots to boost health? Harvard-trained doctor Nick Norwitz, M.D., Ph.D., shares what you need to know about the trending wellness habit.
Sarah Talebagha, M.D., Joins Baptist Health Heart & Vascular Care - Florida Hospital News and Healthcare Report
October 19, 2026 – Vascular surgeon Sarah Talebagha, M.D., has joined Baptist Health Miami Cardiac & Vascular Institute, part of Baptist Health Heart & Vascular Care. Dr. Talebagha specializes in […]
10/19/26 – HAWAIʻI CLIMATE REBATE FINDER HELPS RESIDENTS AND LOCAL BUSINESSES SAVE ON UPGRADES
JOSH GREEN, M.D. GOVERNOR RYAN K.P. KANAKAʻOLE CHAIRPERSON HAWAIʻI CLIMATE REBATE FINDER HELPS RESIDENTS AND LOCAL BUSINESSES SAVE ON UPGRADES HONOLULU – Hawaiʻi households and local businesses now have a direct way to keep more money in their accounts and avoid missing out on valuable financial incentives. The Hawaiʻi State Climate Change Mitigation and Adaptation […]
Michael F. Walsh, M.D., Joins Baptist Health Herbert Wertheim Cancer Institute as Deputy Director and Chief of Prevention - Florida Hospital News and Healthcare Report
October 12, 2026 – Baptist Health Herbert Wertheim Cancer Institute is pleased to welcome Michael F. Walsh, M.D., a board-certified medical geneticist specializing in hereditary cancer predisposition. Dr. Walsh will […]
Niko Kovač extends contract as Borussia Dortmund coach to 2029
DORTMUND, Germany (AP) — Borussia Dortmund has handed coach Niko Kovač a contact extension through June 2029 as a reward for stabilizing the team.Dortmund announced the deal on Tuesday before the Champions League match at Bodø/Glimt — itself a measure of the Berlin-born Croatian coach’s success since taking over when Dortmund was 11th in the Bundesliga in January 2025.
U.S. Department of Health and Human Services (HHS) Recommends Science-Based Thresholds to Target Dangerous Enhanced Kratom Products
Kratom products credit: CDPH DEA takes action based on updated recommendation from HHS October 11, 2026 - WASHINGTON - On Friday, the U.S. Department of Health and Human Services relesed the following: The U.S. Department of Health and Human Services (HHS) provided a new recommendation to the Drug Enforcement Administration (DEA) that establishes science-based thresholds for 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI), potent opioid compounds associated with products marketed as kratom. The Department of Justice today announced that DEA issued new Notices of Intent reflecting HHS’ updated scientific analysis and recommendations, including a new Notice of Intent for 7-OH and MGPI incorporating HHS’ recommended concentration and ratio thresholds. Following a review of available scientific data and comments, HHS Assistant Secretary for Health Admiral Brian Christine, M.D., recommended that DEA use concentration or ratio-based thresholds to determine which products containing 7-OH and MGPI are subject to Schedule I control for purposes of temporary scheduling of these substances under the Controlled Substances Act. The recommendation is designed to target concentrated or chemically altered products while distinguishing them from natural botanical kratom products, which may contain trace amounts of 7-OH and MGPI. “We are drawing a clear line between natural kratom and dangerous, enhanced opioid products,” said HHS Secretary Robert F. Kennedy, Jr. “We listened to the public, followed the science, and developed a clear recommended threshold for temporary scheduling that targets concentrated 7-OH and MGPI without sweeping natural botanical kratom into Schedule I. The Trump Administration will continue taking decisive action against dangerous products that fuel addiction while making sure our policies are grounded in rigorous science.” Under the recommendation, 7-OH and MGPI would be controlled in Schedule I for purposes of temporary scheduling when either substance alone, or their combined amount when both are present: Exceeds 1 milligram per gram in solid powders, encapsulated material, or other solid forms, or exceeds 1 milligram per milliliter in liquid preparations; or When the mass of mitragynine present divided by the mass of 7-OH, or MGPI, or the combined amount of 7-OH and MGPI if both present, is less than 100. The ratio-based approach reflects the alkaloid composition of natural kratom products and provides a way to identify products intentionally enhanced or concentrated with 7-OH or MGPI. Available scientific data indicate that 7-OH occurs naturally in botanical kratom at relatively low or trace levels, while some evidence reviewed by FDA suggests MGPI may also occur at trace levels in some natural or kratom-derived products. FDA's scientific review found that 7-OH is substantially more potent than morphine in preclinical studies, with available data indicating approximately two to nine times greater potency depending on the study. FDA also identified evidence supporting a meaningful risk of opioid-like physical dependence and withdrawal from MGPI. “Our recommendation gives DEA a scientifically supportable framework to distinguish natural botanical kratom from products that have been concentrated or manipulated to deliver dangerous levels of potent opioid compounds,” said Assistant Secretary for Health Admiral Brian Christine, M.D. “This approach allows us to focus on the products that pose the greatest threat to public health.” In July 2025, following an FDA scientific and medical evaluation, HHS recommended that 7-OH above a specified threshold be placed in Schedule I of the Controlled Substances Act. In July 2026, DEA announced its intent to temporarily schedule 7-OH above a specified threshold, and HHS simultaneously sought public comment on the proposed threshold. DEA subsequently temporarily placed MGPI and two synthetic 7-OH derivatives, MGM-15 and MGM-16, in Schedule I. Since then, questions have emerged about how scheduling could affect natural botanical kratom products potentially containing trace amounts of MGPI. The new HHS recommendation responds to those concerns by providing DEA with a more precise threshold based on both the concentration of 7-OH and MGPI and their relationship to mitragynine, the predominant alkaloid in kratom. HHS and FDA will continue working with DEA to protect Americans from dangerous concentrated and synthetic opioid products while ensuring federal policy is grounded in the best available science. Source: HHS
Daniela Lozano, M.D., Joins Baptist Health Kenneth C. Griffin Neuroscience Institute as a Headache Neurologist - Florida Hospital News and Healthcare Report
October 9, 2026 – Board-certified and fellowship-trained neurologist Daniela Lozano, M.D., has joined Baptist Health Kenneth C. Griffin Neuroscience Institute. Her clinical interests include migraine and other headache disorders, women’s […]
How Kaiser Permanente Scales Up Social Health Initiatives
Q&A with KP’s Anand R. Shah, M.D., winner of the 2026 Alliance of Community Health Plans Bernard J. Tyson Health Equity Award
From family practice to business leadership: Dr. Michael App continues his journey at Davenport
Michael App, M.D., is a lifelong resident of Grand Rapids and a busy man. He runs his own private medical practice, leads the largest network of independent physicians in West Michigan, serves as medical director for Interim Hospice and Home Health Care of West Michigan, and is a student at Davenport University.
Baptist Health Breaks Ground on New Home of Kenneth C. Griffin Neuroscience Institute and Announces $75 Million Total Gift to Neuroscience Research and Care - Florida Hospital News and Healthcare Report
Stephen Blumenthal, Board Chair, Baptist Health Foundation ,Alex Villoch, Chief Executive Officer, Baptist Health Foundation ,Michael McDermott, M.D., System Chief Executive of Baptist Health Brain & Spine Care, Chief Medical […]
Claudia Lucchinetti Named Executive Vice President
Claudia F. Lucchinetti, M.D., Executive Vice President for Medical Affairs and the UT Dell Medicine Health System The University of Texas at Austin has
Eva Maria Urrechaga, M.D., Joins Baptist Health Heart & Vascular Care - Florida Hospital News and Healthcare Report
October 6, 2026 – Vascular surgeon Eva Maria Urrechaga, M.D., has joined Baptist Health Heart & Vascular Care at Baptist Health Miami Cardiac & Vascular Institute. She specializes in evaluating […]
Sanford welcomes internal medicine physician to Dickinson
Oct. 6, 2026 Contact: Chelsey Kralicek Sanford Health Media Relations 701-516-4903 / Chelsey.Kralicek@SanfordHealth.org BISMARCK, N.D. —Adokole Otanwa, M.D., an internal medicine physician, specializing in the prevention, diagnosis and treatment of diseases affecting adults, has joined Sanford Dickinson. Dr. Otanwa received his medical degree at the University of Iowa Carver College of Medicine in Iowa City, […]
Broward Health Reaches 100 Cases Using Terumo ROADSAVER™ Carotid Stent System for Stroke Prevention
(Left): Mehdi Bouslama, M.D., with the Broward Health Medical Center team celebrating 100 Cases Using the Terumo ROADSAVER™ Carotid Stent System (Right): Lin Ridwan, M.D., and Malik Fakhar, M.D., with the Broward Health North team celebrating 100 Cases Using the Terumo ROADSAVER™ Carotid Stent System FORT LAUDERDALE, Fla.– Broward Health has reached a major milestone […]
Sanford Black Hills welcomes new women’s health clinician at Haines Ave. Clinic
Sanford Black Hills has expanded its regional healthcare team with the addition of Miranda Pray-Dede, M.D., who is now offering specialized women’s health services at the Sanford Health Haines Ave. Clinic in Rapid City. Dr. Pray-Dede brings more than two decades of dedicated medical experience to patients across the Black Hills region.
Fellowship-Trained Neuro-Oncologist Nishika Karbhari, MD, Joins Baptist Health Herbert Wertheim Cancer Institute
Fellowship-trained neuro-oncologist Nishika Karbhari, M.D., has joined Baptist Health Herbert Wertheim Cancer Institute. Prior to joining Baptist Health, Dr. Karbhari completed a neuro-oncology fellowship at Mayo Clinic in Rochester, MN. She previously completed an internal medicine internship and neurology residency at Dartmouth Health in Lebanon, NH, serving as academic chief resident during her final year. […]
Junney Baeza Dager, MD, Joins Baptist Health Miami Neuroscience Institute as a Nonsurgical Spine Care Physician
Junney Baeza Dager, M.D., has joined Baptist Health Miami Neuroscience Institute at Baptist Health Brain & Spine Care as a nonsurgical spine care physician. Dr. Baeza Dager earned her medical degree from the University of Cartagena School of Medicine in Colombia. After completing a transitional-year internship at St. Vincent of Paul University Hospital in Medellin, […]
Kriti Ahuja, MD, Joins Baptist Health Wertheim Cancer Institute as a Breast Medical Oncologist
Baptist Health Wertheim Cancer Institute is pleased to welcome Kriti Ahuja, M.D., a board-certified medical oncologist specializing in breast cancer. Dr. Ahuja earned her medical degree from Maulana Azad Medical College in New Delhi, India. She completed an internal medicine residency at John H. Stroger, Jr. Hospital of Cook County in Chicago before pursuing a […]
Jared Goldstein, M.D., Joins Baptist Health Urology
September 18, 2026 – Baptist Health is pleased to announce the addition of Jared Goldstein, M.D., a highly skilled urologist and urologic surgeon, to the Baptist Health Urology team. Dr. Goldstein brings to the community extensive expertise in general urology, minimally invasive surgery and men’s health services. Dr. Goldstein specializes in the diagnosis and treatment […]
Glendy Jimenez, M.D., Joins Baptist Health Primary Care as an Internal Medicine Physician
September 15, 2026 – Board-certified internal medicine physician Glendy Jimenez, M.D., has joined Baptist Health Primary Care. Dr. Jimenez provides comprehensive primary care for adults, with a focus on preventive medicine, women’s health and chronic disease management. She is passionate about helping patients prevent illness through early detection, education and personalized care and promoting healthy […]
Brian Grose, M.D., Joins Baptist Health Primary Care as a Family Medicine Physician
September 11, 2026 – Board-certified family medicine physician Brian Grose, M.D., has joined Baptist Health Primary Care. He provides comprehensive primary and preventive care, with clinical interests that include chronic disease management, health optimization and screening for obstructive sleep apnea, diabetes, heart disease and cancer. He is particularly interested in helping patients better understand their […]
Sarah Medley, M.D., Joins Baptist Health Primary Care as a Family Medicine Physician
September 10, 2026 – Board-certified family medicine physician Sarah Medley, M.D., has joined Baptist Health Primary Care. Dr. Medley provides comprehensive primary care for patients across the lifespan, with particular experience caring for adults and older adults. Her clinical interests include women’s health, preventive medicine, chronic disease management, healthy aging and comprehensive outpatient primary care. […]
Claudette Barreto Lopez, M.D., Joins Baptist Health Primary Care as a Family Medicine Physician
Septmeber 8, 2026 – Family medicine physician Claudette Barreto Lopez, M.D., has joined Baptist Health Primary Care. Dr. Barreto Lopez provides comprehensive primary care with an emphasis on preventive medicine and health maintenance. Her clinical interests include women’s health, nutrition and lifestyle medicine, and she works with patients to incorporate sustainable lifestyle changes that support […]
Matthew David Hall, M.D., MBA, Installed as Endowed Chair in Pediatric Oncology at Baptist Health Herbert Wertheim Cancer Institute
September 4, 2026 – Matthew D. Hall, M.D., MBA, lead pediatric radiation oncologist at Baptist Health Herbert Wertheim Cancer Institute, part of Baptist Health Cancer Care, was formally installed as the Endowed Chair in Pediatric Radiation Oncology during a ceremony and reception held September 2 at Mr. C Miami in Coconut Grove. The installation ceremony […]
Kriti Ahuja, M.D., Joins Baptist Health Wertheim Cancer Institute as a Breast Medical Oncologist
September 3, 2026 – Baptist Health Wertheim Cancer Institute is pleased to welcome Kriti Ahuja, M.D., a board-certified medical oncologist specializing in breast cancer. Her clinical interests focus on the comprehensive treatment of patients with breast malignancies, while her research has explored breast cancer, cancer survivorship, second primary malignancies and novel cancer therapies. “We are […]
Junney Baeza Dager, M.D., Joins Baptist Health Miami Neuroscience Institute as a Nonsurgical Spine Care Physician
August 31, 2026 – Junney Baeza Dager, M.D., has joined Baptist Health Miami Neuroscience Institute at Baptist Health Brain & Spine Care as a nonsurgical spine care physician. Board-certified in physical medicine and rehabilitation with specialized expertise in spinal cord injury medicine, Dr. Baeza Dager focuses on helping people with neurological conditions improve their function, […]
Nathan J. Nordmann, M.D., Joins Baptist Health Miami Neuroscience Institute as Director of Spinal Oncology and Co-Director of Spinal Radiosurgery
August 27, 2026 – Fellowship-trained neurosurgeon Nathan J. Nordmann, M.D., has joined Baptist Health Miami Neuroscience as director of spinal oncology and co-director of spinal radiosurgery. He specializes in the surgical treatment of conditions affecting the brain and spine, with advanced expertise in primary and metastatic spinal tumors, complex spinal pathology and minimally invasive surgical techniques. […]
Harel Deutsch, M.D., Joins Baptist Health Miami Neuroscience Institute as Director of Spine Surgery
August 24, 2026 – Fellowship-trained, board-certified neurosurgeon Harel Deutsch, M.D., has joined Baptist Health Miami Neuroscience Institute as director of spine surgery. An internationally recognized leader in spinal surgery, Dr. Deutsch specializes in minimally invasive spine surgery, motion preservation surgery and the treatment of failed back surgery syndrome. He brings nearly three decades of experience […]
Mary Klotman, Duke's Chief Academic Health Leader, will Complete Service in 2027
DURHAM, N.C. – After two decades in senior leadership at Duke and 10 years as dean of the Duke University School of Medicine, Mary E. Klotman, M.D., will complete service on June 30, 2027.
Winning Her Fight Against Endometrial Cancer with Broward Health
Scott Jordan, M.D., and Lizbeth Muller Sept 29, 2026 – Miami businesswoman Lizbeth Muller, 60, proudly holds the title of endometrial cancer survivor. The most common type of gynecologic cancer, endometrial cancer affects the lining of the uterus (endometrium). Lizbeth was diagnosed in 2023 after noticing some unusual symptoms. “I stopped having periods years earlier, […]
Sanford Health Welcomes New Pediatrician to Rapid City Clinic
Elizabeth Farnsworth, M.D., has joined Sanford Black Hills and is providing care to patients at the Sanford Health Jordan Drive Clinic in Rapid City, offering pediatric primary care services for infants, children and adolescents in the Black Hills region.
Drs. Zachary Daily and Sana Shaukat Join Baptist Health Primary Care as Internal Medicine Physicians
Internal medicine physicians Zachary Daily, D.O., and Sana Shaukat, M.D., have joined Baptist Health Primary Care. Prior to joining Baptist Health, Dr. Daily completed his internal medicine residency training at Florida Atlantic University in Boca Raton. He earned his Doctor of Osteopathic Medicine degree from Lake Erie College of Osteopathic Medicine in Bradenton, FL, and […]
Heart-brain protection during cardiac surgery pioneer to receive the 2026 Basic Research Prize
DALLAS, Sept. 21, 2026 — A pioneering researcher known for her work to protect the heart and brain during cardiac surgery will be recognized by the American Heart Association at its annual...
Culturally Relevant Cardiovascular Disease Prevention and Care Strategies
(Feature Impact) Driven by rising rates of obesity, diabetes, high blood pressure and other risk factors, cardiovascular disease has surpassed cancer as the leading cause of death among Hispanic adults in the United States. googletag.cmd.push(function() { googletag.display('fixed-big-ad-top-asset'); }); Hispanic people represent nearly 1 in 5 of the U.S. population and are the nation’s largest ethnic minority group, yet many continue to face barriers to achieving heart health and accessing high-quality healthcare. A new scientific statement published in the American Heart Association’s flagship journal, “Circulation,” revealed how social, economic, cultural and environmental factors contribute to persistent disparities in cardiovascular health, calling for culturally tailored prevention strategies, equitable access to care and greater representation of Hispanic populations in cardiovascular research.“Hispanic populations in the U.S. are incredibly diverse even within their own communities with differences in genetic ancestry, language, cultural traditions and social experiences that can significantly influence cardiovascular health,” said Johanna Contreras, M.D., M.Sc., FAHA, director of the Division of Heart Failure and medical director of the Hispanic Heart Center within the Mount Sinai Health System. “Yet Hispanic people remain underrepresented overall in the research that guides prevention and treatment strategies… Without better representation and more detailed data, we risk overlooking important differences that can help us improve care and save lives.”Hispanic Cardiovascular Health by the NumbersCardiovascular risk factors – obesity (nearly 46%), type 2 diabetes (15.5%) and high blood pressure (approximately 44%) – are prevalent among Hispanic adults and often emerge at younger ages and occur more frequently among Hispanic adults compared with white adults.According to the report, only about 1 in 5 Hispanic adults achieves ideal cardiovascular health as defined by the American Heart Association’s original Life’s Simple 7 metrics. Updated analyses using the Life’s Essential 8 framework demonstrated persistent disparities for heart and brain health, as well as suboptimal dietary quality, sleep patterns and levels of physical activity.Social and Economic Barriers MatterBiology alone does not explain cardiovascular health disparities. The environments where people live, work and age, along with social and economic challenges, impact heart health. In fact, approximately 17% of Hispanics live below the federal poverty threshold, compared with 8.2% of white adults. googletag.cmd.push(function() { googletag.display('fixed-big-ad-middle-asset'); }); “Many Hispanic adults face obstacles that extend far beyond the doctor’s office,” Contreras said. “Limited health insurance coverage, language differences, food insecurity, environmental exposures and concerns related to immigration status can make it more difficult to prevent disease, manage chronic conditions and receive timely treatment.”Contreras emphasized the cultural values and practices of Hispanic people also influence how they perceive their health and healthcare options.“Family plays a central role in many Hispanic communities and can be an extraordinary source of strength, support and resilience,” Contreras said. “At the same time, family members are often called upon to translate medical information, navigate health systems and help make healthcare decisions for loved ones. Those responsibilities can shape how health information is understood and acted upon.”An Action Plan for Improving Hispanic HealthThere are practical opportunities to achieve equitable cardiovascular health and reduce disparities through community engagement, culturally responsive care, inclusive research and policies that address the underlying drivers of health.“Reducing cardiovascular disease among Hispanic populations demands action at every level,” Contreras said, “from improving access to culturally responsive care and expanding research participation to addressing the social and environmental conditions that shape health.”By addressing both medical risk factors and the social conditions that shape health, experts believe there is an important opportunity to reduce disparities and help more people live longer, healthier lives. Learn more at Heart.org.Photo courtesy of Shutterstock googletag.cmd.push(function() { googletag.display('fixed-big-ad-bottom-asset'); });
Culturally Relevant Cardiovascular Disease Prevention and Care Strategies
(Feature Impact) Driven by rising rates of obesity, diabetes, high blood pressure and other risk factors, cardiovascular disease has surpassed cancer as the leading cause of death among Hispanic adults in the United States.Hispanic people represent nearly 1 in 5 of the U.S. population and are the nation’s largest ethnic minority group, yet many continue to face barriers to achieving heart health and accessing high-quality healthcare. A new scientific statement published in the American Heart Association’s flagship journal, “Circulation,” revealed how social, economic, cultural and environmental factors contribute to persistent disparities in cardiovascular health, calling for culturally tailored prevention strategies, equitable access to care and greater representation of Hispanic populations in cardiovascular research.“Hispanic populations in the U.S. are incredibly diverse even within their own communities with differences in genetic ancestry, language, cultural traditions and social experiences that can significantly influence cardiovascular health,” said Johanna Contreras, M.D., M.Sc., FAHA, director of the Division of Heart Failure and medical director of the Hispanic Heart Center within the Mount Sinai Health System. “Yet Hispanic people remain underrepresented overall in the research that guides prevention and treatment strategies… Without better representation and more detailed data, we risk overlooking important differences that can help us improve care and save lives.”Hispanic Cardiovascular Health by the NumbersCardiovascular risk factors – obesity (nearly 46%), type 2 diabetes (15.5%) and high blood pressure (approximately 44%) – are prevalent among Hispanic adults and often emerge at younger ages and occur more frequently among Hispanic adults compared with white adults.According to the report, only about 1 in 5 Hispanic adults achieves ideal cardiovascular health as defined by the American Heart Association’s original Life’s Simple 7 metrics. Updated analyses using the Life’s Essential 8 framework demonstrated persistent disparities for heart and brain health, as well as suboptimal dietary quality, sleep patterns and levels of physical activity.Social and Economic Barriers MatterBiology alone does not explain cardiovascular health disparities. The environments where people live, work and age, along with social and economic challenges, impact heart health. In fact, approximately 17% of Hispanics live below the federal poverty threshold, compared with 8.2% of white adults.#placement_976606_0_i{width:100%;max-width:550px;margin:0 auto;}var rnd = window.rnd || Math.floor(Math.random()*10e6);var pid976606 = window.pid976606 || rnd;var plc976606 = window.plc976606 || 0;var abkw = window.abkw || '';var absrc = 'https://ads.empowerlocal.co/adserve/;ID=181918;size=0x0;setID=976606;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid976606+';place='+(plc976606++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER';var _absrc = absrc.split("type=js"); absrc = _absrc[0] + 'type=js;referrer=' + encodeURIComponent(document.location.href) + _absrc[1];document.write('');“Many Hispanic adults face obstacles that extend far beyond the doctor’s office,” Contreras said. “Limited health insurance coverage, language differences, food insecurity, environmental exposures and concerns related to immigration status can make it more difficult to prevent disease, manage chronic conditions and receive timely treatment.”Contreras emphasized the cultural values and practices of Hispanic people also influence how they perceive their health and healthcare options.“Family plays a central role in many Hispanic communities and can be an extraordinary source of strength, support and resilience,” Contreras said. “At the same time, family members are often called upon to translate medical information, navigate health systems and help make healthcare decisions for loved ones. Those responsibilities can shape how health information is understood and acted upon.”An Action Plan for Improving Hispanic HealthThere are practical opportunities to achieve equitable cardiovascular health and reduce disparities through community engagement, culturally responsive care, inclusive research and policies that address the underlying drivers of health.“Reducing cardiovascular disease among Hispanic populations demands action at every level,” Contreras said, “from improving access to culturally responsive care and expanding research participation to addressing the social and environmental conditions that shape health.”By addressing both medical risk factors and the social conditions that shape health, experts believe there is an important opportunity to reduce disparities and help more people live longer, healthier lives. Learn more at Heart.org.Photo courtesy of Shutterstock
Help Was Nearby: Athlete, 25, Survives Near-Fatal Aortic Tear
When Danny Cruz, 25, suffered a near-fatal tear in his aorta, he was lucky help was nearby—at Baptist Health Bethesda Hospital East and at Boca Raton Regional Hospital, where Bradley Taylor, M.D., performed life-saving surgery.
University of Michigan Health cardiologist named to U.S. Preventive Services Task Force
University of Michigan Health cardiologist Venkatesh Murthy, M.D., Ph.D., has been appointed to the U.S. Preventive Services Task Force.
What Does the Science of Climate Change Really Look Like?
Editor’s Note: This is the second in a three-part series on how the Right should think about environmental and climate policy. Read Chris Barnard on Reclaiming Environmental Policy from the Left. More than a decade ago, the world’s governments negotiated and signed the Paris Climate Agreement, committing to hold global warming well below 2 degrees Celsius. In the following years, climate had immense cultural power. Greta Thunberg emerged. Fortune 500 companies established net-zero plans. The U.S. got the Inflation Reduction Act. Then the pendulum swung back. President Donald Trump returned to the Oval Office, speaking of green energy as a “scam” and carbon footprints as a “hoax” and on all matters of international policy emphasizing bilateral engagement and power over globalism and cooperation. The technology companies that had been at the forefront of net-zero pledges and green leadership discovered the importance of all-of-the-above power to their visions for artificial intelligence and began quietly postponing or removing their targets. On the left side of the political spectrum, rising concerns about inflation and cost pushed climate lower down in the stated priorities of voters and stump speeches of politicians. The moment is ripe for a reset on the politics of climate change and for conservatives especially to chart a course that acknowledges and addresses the real challenges in plausible ways. So what should we think about climate change as we enter a post-peak climate era? If it is neither an apocalypse nor a hoax, what will hold up as a durable view of climate change? And how does it project onto the concerns and priorities of the right-of-center’s emerging coalition? New to Commonplace_? Subscribe below to get the magazine in your inbox._ Subscribe A Solid Foundation As the politics and economics of climate careened over the past ten years, the physics carried on regardless. In 2015, the year the Paris Climate Agreement was adopted, the world emitted 41.2 gigatonnes of carbon dioxide. By 2025, emissions had risen only 2.4%, to 42.2 gigatonnes, because falling emissions from land use offset increasing emissions from fossil fuels. But slow growth in annual emissions is not rapid decline, let alone net-zero, so carbon dioxide kept accumulating in the atmosphere, going from 399 to 426 parts per million. Global temperature kept rising too, from about 1.1 degrees Celsius above the 1850–1900 average in 2015, to 1.4 degrees above it in 2025. None of this should surprise anyone. Even most prominent skeptics, like the authors of the 2025 report commissioned by the Trump administration’s Department of Energy, accept the basic physics. Carbon dioxide added to the atmosphere at industrial volumes accumulates and traps heat that would otherwise escape to space. That heat warms the upper ocean and increases temperatures at the surface. Increased ocean heat and melting of land ice cause sea levels to rise. Changes in the climate become noticeable to us as subtle shifts in temperature and precipitation, seasons arriving early or late, changes in the surrounding ecosystem, and weather extremes. The much more meaningful debate is not about whether these things are happening, but about what it all means for human societies. (While it is a proxy measure of overall risk, no one experiences global surface temperature.) This debate invokes at least three interesting questions: how much today’s warming is showing up in regional climate trends, how much more warming we should anticipate, and how extreme weather events can be understood in the context of climate change. Recent scientific advances give us new insights into each of these, but there is still much to learn. This is the context in which the next generation of conservative leaders will be the first to deal with significant climate change as a fact, not a forecast. It will be with them for their entire careers. Our evolving scientific picture of climate change will come from weather and climate records stretching further into the past, new kinds of observations in the present, better modeling tools for the future, and simply more time to observe the emergence of climate signals and their tangible effects on ecosystems and communities in the United States and around the world. The policy landscape will be shaped by not only the impacts of changes in the climate, but also by the ways in which societies respond and by the emergence of new technologies for both altering the trajectory of emissions and adapting to new climate realities. Global climate records now show the fingerprints of warming in different phenomena around much of the world. The IPCC, in its most recent assessment report, documents warming trends over all land regions, even as natural variability adds substantial variance to local trends. And the highest temperature extremes have become more intense and frequent, almost everywhere, since the 1950s. Scientists are highly confident that these changes are attributable to human influence. But confidence in detecting trends and attributing them to human influence degrades across heavy precipitation events; drought trends are heterogeneous and not attributable to human activity with great confidence. For hurricanes, tornadoes, and other severe storms there is even less confidence in trends or their relationship to climate change. In general, a fair summary of the evidence is that for well-observed phenomena, like surface temperature or heavy rainfall, with a clear relationship to warming, our multidecadal observations are consistent with human influence overcoming natural variability over long time periods and extremes increasing. For regions that are sampled more sparsely, or phenomena with a higher noise-to-signal ratio, we will need to observe them longer to understand the magnitude of the climate signal or improve dynamical understanding using models and observations together. But for Climate For those who can’t wait, we also have new techniques that attempt to understand the role climate change has in influencing particular extreme events. When the climate is changing and disaster strikes, it is natural to ask whether that disaster was somehow “caused” by climate change. For scientists and policymakers acting in good faith, answering that question helps develop a more accurate picture of the problem, how it may be getting worse, and what preparations we should be making to respond to it. It may, at some point, give some weight to how liability is assigned by courts or adaptation funding is distributed by society. But how we ask this question is extremely important. It is easy to get the analysis wrong by discounting the role that meteorology plays. As meteorologist Theodore Shepherd explained in a clear 2016 review of climate attribution methods, “if a weather or climate event is truly extreme in the present climate, then perforce it requires unusual meteorological conditions, which means that climate change is at most a contributing factor.” Share Scientists have two ways to probe climate as a contributing factor, both of which have entered media coverage of extreme weather events. One asks a probabilistic question: How much more likely is a particular event (e.g., a temperature record over a particular area) amid global warming? The answer involves using historical records and computer simulations to estimate the likelihood of such an event in both a changed and a preindustrial climate. The findings are less about the specific event, and more about events of that nature. The other question is: How has the changed climate affected the specific event in question? Here, scientists try to understand what a similar event would have looked like in the preindustrial climate. This is sometimes called the storyline approach, where the story is the specific meteorological details of the event. These methods offer ways to test the intuition of scientists about real weather extremes. In late June and early July of 2021, a persistent high-pressure ridge, or heat dome, set up over the Pacific Northwest and an extraordinary heat wave affected the area from Oregon to British Columbia. For six days, it shattered temperature records across the region and hundreds died from heat-related causes, in an area where such high, and persistently high, temperatures were well outside of experience and many live without air conditioning. Scientists have studied its connection to climate change using multiple approaches. This specific event was created by a rare combination of meteorological factors, a strong high-pressure ridge created the conditions for extreme heat, which occurred on top of higher average temperatures in the region from global warming. Probabilistic analyses showed that climate change increased the likelihood of such an event by at least 8-fold to more than 100-fold. One standout example found that such an event had effectively zero probability of occurring in the preindustrial climate. The enormous range in these assessments reflects how hard it is to estimate probabilities of events at the tail of the historical record. Estimates of the effect on the temperature of the event are more clustered. A recent review paper documents how multiple methodologies have found a positive influence, roughly 1-2 degrees Celsius of an anomaly that exceeded 15 degrees, of climate change on the temperature magnitude of the event. Multiple studies have investigated and found some positive influence of climate change in other extreme events. Attribution studies found climate likely increased the heavy rainfall that accompanied Hurricane Helene in North Carolina and surrounding regions in 2024. The extensive fires that struck Los Angeles in 2025 illustrate how the causal chain can become messy, though. Studies do detect a positive influence of climate on the event’s likelihood, but while climate change likely contributed to underlying aridity, it would not have played a role in the heavy winds or land practices that preceded disaster. These event attribution studies will become more common for extreme, or damaging, weather events. They can be produced quickly, and often are reported before peer review. As the Pacific Northwest heatwave example shows, when multiple methods converge on a positive attribution, the finding should probably carry some weight even if you have to be careful about accepting the results from a single study. I expect that as climate change proceeds and the climate thus departs further from a preindustrial counterfactual, the influence will become more detectable across a variety of extreme events and more easily identified. This will be used to cast blame, but can also be used to inform how communities and society adapt to ongoing change. We May Still Be Surprised One positive development, insofar as less climate change is better, has been that our central estimates for future climate change should probably be revised downward. Mostly, that is because the high-end warmings that scientists regularly analyzed about ten to 20 years ago, driven by high emissions throughout the twenty-first century, now appear to be somewhere between unlikely and impossible. At one time, the upper end of mainstream climate projections extended well into 4 to 6 degrees Celsius of warming by the end of this century, which, models suggest, would have wrought enormous real-world damage. Current energy and policy trends now point toward 2.5 or 3 degrees. Damages and risks are commonly modeled as increasing steeply with more warming, so this is already a better-than-previously-expected outcome for the climate (which is independent of the physical response to emissions). But we should maintain a wide range for plausible outcomes and prepare for the possibility of being surprised. Emissions trajectories are subject to deep uncertainty, the physical climate response is still developing, and whatever change occurs in the climate will then be mediated through unpredictable economic, social, and political institutions. Over the past decade, the pace of warming surprised some keen observers and appeared to accelerate, though not yet outside the range of expectation provided by climate models. The reasons for that apparent acceleration are being actively studied (as was the apparent pause in warming from 1998 to 2012), but no single driver has emerged. Some blame it on the El Niño, variability which would have no bearing on climate. Some think it is a result of factories in East Asia and global shipping fleets cutting aerosol emissions, which in the strongest version of the argument would indicate higher climate sensitivity to carbon-dioxide emissions. Others are more measured, not yet ready to draw solid conclusions as to whether climate projections require revision. We will have to see. Long-Term Thinking Climate change asks us to think over long time scales. But the pace of human-driven warming is compressing a large global change into a century. Changing weather patterns and extreme events are already causing adjustment costs and damages and will do more. Adaptation will help, but it is not free. For some communities, these costs will erode livelihoods and well-being, and may force migration. Are we prepared for large-scale managed retreats in the United States? Thankfully, American wealth, geographical diversity, and moderate climates may leave us better prepared than many around the world. But wealthy countries can still suffer serious disruption from narrowly concentrated costs, even if they appear entirely manageable in aggregate. Readers of Commonplace are familiar with the challenges of rapidly adapting to economic forces. The displacement that came from the China Shock is barely perceptible in aggregate GDP and employment data, but it affected millions of people and those people were far less mobile than economic models tended to assume. Deindustrialization rippled through the nation with enormous effects for not only our economic vitality, but also our national security. The forces surrounding climate change may not be so different; the world gets richer and must accept some diffuse costs. Those may be modest overall, but cause all manner of unpredictable effects with which policymakers must cope. In the case of the China Shock, our faith in a growing pie served us poorly. We’ll need to do better on climate. Leave a comment
Devils Re-Sign Rising Forward Luke Evangelista
The New Jersey Devils have re-signed rising forward Luke Evangelista to a long-term contract extension, keeping him in the “Garden State.”The Devils acquired Evangelista from the Nashville Predators during the offseason for a first-round pick and a second-round pick. Now, he has committed to New Jersey long-term.Devils Re-Sign Luke EvangelistaThe Devils officially announced via their […] The post Devils Re-Sign Rising Forward Luke Evangelista appeared first on HEAVY.
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.
Quantum Health Names Dr. Susan Mani as Chief Medical Officer
DUBLIN, Ohio, September 15, 2026--Quantum Health, the industry-leading healthcare navigation company, today announced the appointment of Susan Mani, M.D., as Chief Medical Officer. Dr. Mani will shape Quantum Health's clinical strategy, working to improve healthcare experiences, results and affordability for members and clients.
Quantum Health Names Dr. Susan Mani as Chief Medical Officer
Quantum Health, the industry-leading healthcare navigation company, today announced the appointment of Susan Mani, M.D., as Chief Medical Officer. Dr. Mani w...
BioMarin appoints Robert Plenge to its Board and Science & Technology Committee
BioMarin appointed Robert Plenge, M.D., Ph.D., to its Board of Directors and to the Science and Technology Committee, effective September 10, 2026.Original SEC Filing: BIOMARIN PHARMACEUTICAL INC [ BMRN ] - 8-K - Sep. 14, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…
Healthy Living with USA Health: Enlarged Prostate Treatment Options
In this Healthy Living, we talk with Troy M. Sofinowski, M.D., an Endourologist at USA Health.
Dana White Comments on Michael Page’s UFC Future
UFC president Dana White confirmed that the promotion has no interest in re-signing Michael Page after the conclusion of his contract.Page just finished his six-fight UFC contract with a 5-1 record, but his fights were not exciting to watch, and the UFC had no interest in re-signing him.Dana White Confirms Michael Page Is No Longer […] The post Dana White Comments on Michael Page’s UFC Future appeared first on HEAVY.
Williamson Health Medical Group welcomes Family Medicine physician Michael Swiercz, M.D.
FRANKLIN – Williamson Health Medical Group is pleased to announce the recent addition of Michael Swiercz, M.D., to its growing team of providers. Dr. Swiercz will work alongside Arthur Williams,
Luminis Health Working to Restore Systems After Cyberattack
Luminis Health in Maryland is investigating a cyberattack that has taken certain systems offline. Data breaches have been announced by Texas Orthopedic Luminis Health in Maryland is investigating a cyberattack that has taken certain systems offline. Data breaches have been announced by Texas Orthopedic surgeon Jeffrey David Reuben, M.D, Well Child in Tennessee, and Horizon Eye Care Laser & Eye Surgery Center in New Jersey.
Marshall Health performs first roboticassisted shoulder replacement surgery in WV
HUNTINGTON, W.Va. — Marshall Health Network Orthopaedic Surgeon John J. Jasko, M.D., performed West Virginia’s first robotic arm-assisted shoulder replacement surgery using Mako SmartRobotics this week. Known as Mako Shoulder, […]
Black Business Month Honoree
Official website of Senator Akilah Weber Pierson, M.D., representing California Senate District 39.
Pascack Valley Medical Center Expands Advanced Women’s Health Services with Addition of Urogynecologist and Minimally Invasive Gynecologic Surgeon Mamta M. Mamik, M.D., M.Sc., FACOG, FACS
Pascack Valley Medical Center is pleased to welcome Mamta M. Mamik, M.D., M.Sc., FACOG, FACS, a board-certified and highly trained gynecologic surgeon whose expertise spans female pelvic medicine and reconstructive surgery, neuropelveology, endometriosis, fibroids, chronic pelvic pain, and minimally invasive gynecologic surgery.
Murphy & Schrier Advocate for Patient-First American Approach to Health Care
WASHINGTON, DC – As health care costs continue to rise across the country, Congressman Greg Murphy, M.D. (R-NC-03), Chair of the GOP Doctors Caucus, and Con ...
Marshall Health Network adds five pediatricians to its care team
HUNTINGTON, W.Va. – Marshall Health Network recently welcomed five pediatricians to its team of providers. Rita M. Ryan, M.D., professor and chair of pediatrics at the Marshall University Joan C. Edwards School of Medicine, is a board-certified neonatologist and nationally recognized neonatal lung specialist. She brings extensive experience as a clinician and pediatric leader, including previous service as pediatrician-in-chief at the Medical […]
UToledo College of Pharmacy and Pharmaceutical Sciences Welcomes Largest Pharm.D. Class in 5 Years
White Coat Ceremony marks the start of the professional journey for 135 incoming pharmacy and pharmaceutical sciences students.
Texas Tech University Health Sciences Center Awarded Grant to Improve Diabetes Testing Access in Rural West Texas
The American Medical Association (AMA) awarded $50,000 to Adrian Billings, M.D., Ph.D., as part of a new grant to improve access to A1C testing in West Texas.
Brenda and Robert Gullett Jr. Gift Supports UAMS Orthopaedic and Sports Medicine Facility
LITTLE ROCK — The University of Arkansas for Medical Sciences (UAMS) received a $1 million gift from Brenda Gullett and Robert R. Gullett Jr., M.D., associate professor and orthopaedic surgeon at the UAMS Northwest Regional Campus, to benefit the UAMS Health Orthopaedic & Sports Medicine Hospital in Springdale. “A lifetime…
Lions’ Ennis Rakestraw Fires Back After Subpar Ranking
The Detroit Lions already have their first preseason game in the books, having dropped a 16-14 final score against the Cincinnati Bengals on Thursday evening at Paycor Stadium.During the contest, the Lions were comprised mostly of reserve players hoping to make a good enough impression upon the club’s coaching staff to earn a coveted roster […] The post Lions’ Ennis Rakestraw Fires Back After Subpar Ranking appeared first on HEAVY.
How Serena Raj Found Her Calling at the Intersection of Medicine and Public Health
Miller School M.D./M.P.H. student Serena Raj combines a passion for pediatrics and patient advocacy as she strives to improve care outcomes.
Reappointment of Senior Vice Chancellor of UCLA Health Sciences John Mazziotta - UCLA Office of the Chancellor
Chancellor Julio Frenk shared this message with faculty and staff. Dear Colleagues: I am pleased to announce that John Mazziotta, M.D., Ph.D., has been reappointed for a five-year term and will now serve as senior vice chancellor of UCLA Health...
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Family Medicine Physician Charles Jones, M.D., Joins UAMS Health Family Medical Center in Helena-West Helena
Charles Jones, M.D., has joined the University of Arkansas for Medical Sciences (UAMS) Family Medical Center in Helena-West Helena, where he will offer primary care for all ages.
Science Under the Sword of Damocles
By Sam Halpern, M.D. I have spent my working life in medicine as a clinician and a medical scientist. I have watched with awe as basic and applied medical science placed new and effective tools in…
Science Under the Sword of Damocles
By Sam Halpern, M.D. I have spent my working life in medicine as a clinician and a medical scientist. I have watched with awe as basic and applied medical science placed new and effective tools in…
Health system leaders discuss care delivery, workforce and technology at 2026 AHA Leadership Summit
Following an introduction from Michelle Hood, AHA executive vice president and COO, moderator Chris DeRienzo, M.D., AHA senior vice president and chief physician executive, led a panel discussion July 14 at the 2026 AHA Leadership Summit with Betty Chu, M.D., senior vice president and chief medical officer of Advocate Health; Christine Donohue-Henry, M.D., chief population health officer of ChristianaCare; and Bill Gassen, president and CEO of Sanford Health, and AHA chair-elect.
AHA recognizes award-winning hospitals and health systems
AHA Chair Marc Boom, M.D., presented three AHA awards during the 2026 Leadership Summit, recognizing hospitals and health systems for innovation, advancing health and excellence. See the news releases for more details on the winners and honorees.
Primus Mbawuike, M.D., Pharm.D., Joins UAMS Health Family Medical Center in Pine Bluff
Primus Mbawuike, M.D., Pharm.D., has joined the University of Arkansas for Medical Sciences (UAMS) Family Medical Center in Pine Bluff where he will offer comprehensive care for all ages with additional expertise in pharmacy.
Politics: What Donald Trump’s Defense Policy Means For Black Service Members
Black Americans serving in the U.S. military have long lived with a great contradiction. The country they’re fighting to protect is the same one that’s failed to serve and protect them.Despite this, Black Americans continue to enlist. There are over 350,000 Black active duty and select reserve members and more than 2.4 million Black veterans. That’s according to the Institute for Veterans and Military Families at Syracuse University.This year, Defense secretary Pete Hegseth has blocked or delayed the promotions of more than a dozen Black and female senior officers. He’s also dismissed several high-ranking Black and female officers, according to The Atlantic. This comes amid the second Trump administration’s aggressive rollback of programs and policies connected to diversity, equity and inclusion.Black military members have always battled discrimination. But for some, this is a step too far in the wrong direction. So, what does their future hold? And what does it mean for the U.S. military?Find more of our programs online. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a.
Miller-Meeks Joins Governor Reynolds to Announce Major Milestone for Rural Health Care in Iowa
Congresswoman Mariannette Miller-Meeks, M.D. joined Governor Kim Reynolds in Muscatine to announce that Iowa has become the first state in the nation to fully allocate its first-year funding from the Rural Health Transformation Program created through the Working Families Tax Cuts.
What Science Knows About Grief
After my husband’s death, I had never been more pliable, tender, open, or raw. It was then that I tried E.M.D.R. therapy.
Watkins honored with top national bone health award
MORGANTOWN, W.Va. – Colleen Watkins, M.D., a WVU Medicine rheumatologist, has been named the 2026 Andrew D. Bunta Own the Bone Clinician of the Year by the American Orthopaedic Association. Colleen Watkins, M.D. ...
Science, Public Health, and the Politics of Truth
Presented as part of the McCloskey Speaker Series.Peter Hotez, M.D., Ph.D., professor and dean of the National School of Tropical Medicine at Baylor College of Medicine, joins the Aspen Institute for a keynote lecture on the intersection of science, medicine, and public trust. A leading authority on vaccines and neglected tropical diseases, Hotez reflects on the challenges facing public health today, the growing politicization of science, and what it will take to rebuild trust in scientific institutions in the years ahead.Paepcke Auditorium, doors at 5:00 pmRegistrationThis event is free and open to the public, but registration is required, and capacity is established on a first-come, first-served basis. Once an event is at capacity, we will have an in-person waitlist at the door.Public registration is now open for summer 2026. Please click here to register.ParkingParking is very limited. Please carpool, walk, bike, or ride RFTA.Book signing will immediately follow the event. To learn more about his book or to order a copy, please click here.
Science, Public Health, and the Politics of Truth
Presented as part of the McCloskey Speaker Series.Peter Hotez, M.D., Ph.D., professor and dean of the National School of Tropical Medicine at Baylor College of Medicine, joins the Aspen Institute for a keynote lecture on the intersection of science, medicine, and public trust. A leading authority on vaccines and neglected tropical diseases, Hotez reflects on the challenges facing public health today, the growing politicization of science, and what it will take to rebuild trust in scientific institutions in the years ahead.Paepcke Auditorium, doors at 5:00 pmRegistrationThis event is free and open to the public, but registration is required, and capacity is established on a first-come, first-served basis. Once an event is at capacity, we will have an in-person waitlist at the door.Public registration is now open for summer 2026. Please click here to register.ParkingParking is very limited. Please carpool, walk, bike, or ride RFTA.Book signing will immediately follow the event. To learn more about his book or to order a copy, please click here.
OHSU selects chief executive officer of OHSU Health system
Announcement from OHSU President Shereef Elnahal, M.D., M.B.A.
Thomas Best, M.D., Ph.D., Earns ACSM Honor Award for Transforming Sports Injury Recovery
Dr. Thomas Best receives ACSM’s highest honor for pioneering sports injury recovery research and mentoring the next generation of clinicians.
Mark Nelson, Ph.D., Elected to the UK’s Academy of Medical Sciences
Mark Nelson, Ph.D., University Distinguished Professor and chair of pharmacology at the Robert Larner, M.D. College of Medicine at the University of Vermont, has been named a 2026 Fellow of the Academy of Medical Sciences.
Marshall Health Network, Intermed Labs advance next-generation surgical visualization through spatial arthroscopy
HUNTINGTON, W.Va. – Marshall Health Network, in collaboration with Intermed Labs (IL), has announced the development of spatial arthroscopy, an innovative technology designed to transform how surgeons visualize and interact with minimally invasive procedures. The project, currently in development, was conceptualized by Chad D. Lavender, M.D., and represents a new frontier in surgical ergonomics and digital […]
UAMS College of Public Health Celebrates Class of 2026
The smiles and hugs were plenty as the University of Arkansas for Medical Sciences (UAMS) Fay W. Boozman College of Public Health recognized its newest graduates during its 2026 commencement at Little Rock’s Arkansas Museum of Fine Arts. There were 72 graduates in this year’s class. Stephanie Gardner, Pharm.D., Ed.D.,…
Violence should never be part of the job in health care: Fawad Taj
The health care profession that has quietly endured violence for years is finally beginning to say, out loud, that this should never have been considered normal in the first place, writes guest columnist Dr. Fawad Taj, M.D., a psychiatrist, Cleveland resident, and community advocate.
TTUHSC’s Klein Selected to Leadership Role by the Texas Pharmacy Association
The Texas Pharmacy Association announced (May 19) the appointment of Mary Klein, Pharm.D., as assistant vice president of Strategic Initiatives and Practice Innovation.
TheBodyPro: Can gene therapy control HIV? Steven Deeks, M.D., explains the science
A single dose of anti-HIV duoCAR-T cellular therapy is safe — and might lead to sustained control of HIV in the absence of any ART in some individuals.
Auditor warns El Paso ISD health insurance fund is $19 million short amid deficit
As the El Paso Independent School District grapples with a $52 million budget deficit, it also has another problem.During the
Commencement 2026: Pharmacy graduate combines passion for care with business acumen to provide total patient support
KINGSTON, R.I. — May 12, 2026 — For Alayna Ballavia, who will graduate from the University of Rhode Island with two advanced degrees—including a Pharm.D. from the College of Pharmacy—some of the most meaningful lessons she learned about pharmacy, healthcare, and life in general happened far beyond the classroom. During two international medical missions in […]
Brewing Better Health Episode 5: Why Data and Trust Matter in Public Health
Matt Strickland, Ph.D., and Dean Muge Akpinar-Elci, M.D., MPH, discuss how data, risk and communication shape public health decisions.
Dr. Perry appears on Kids These Days RVA - Richmond City Health Department
RHHD Director Elaine Perry, M.D. appeard on ABC 8’s new podcast Kids These Days RVA to discuss the importance of infant immunization.
Huff-Lonergan, Hansen, Keating selected for endowed positions in animal science
Elisabeth Huff Lonergan, University Professor of animal science, was named the Morrison Chair in Meat Science. Stephanie Hansen, professor of animal science, and Aileen Keating, professor of animal science, will hold the title of Tyrone D. Artz, M.D., Chair for Faculty Excellence in Animal Science.
LOCAL SPOTLIGHT: Cassidy Highlights Local Business Owner’s Journey from Uncertainty to Entrepreneurship | U.S. Senator Bill Cassidy
WASHINGTON – U.S. Senator Bill Cassidy, M.D. (R-LA), for his monthly Local Spotlight, recognized Amanda Ratcliff for her resilience and entrepreneurial spirit in turning life’s challenges into opportunity. Her business, Buttery Spell, features uniquely crafted products that reflect her creativity and the unmistakable flavors and culture of New Orleans. Each month, Cassidy highlights a local story that truly […]
Browns draft: Best available on Day 3, Jermod McCoy concerning health update
Day 3 of the NFL draft kicks off at noon. Best available players for the Cleveland Browns, a Jermod McCoy health update
HHS Regional Director Visits FAU to Witness Health Impact in Action
FAU hosted HHS regional director and alumna Samantha Brown-Parks, M.D., to its Boca Raton campus for a visit highlighting workforce training, research and community health initiatives.
AHA chair speaks at Politico Health Care Summit
Marc Boom, M.D., president and CEO of Houston Methodist and 2026 AHA board chair, spoke today at POLITICO’s Health Care Summit about health care affordability.
AI in health care: Experts discuss the future of AI practices and policies
Jim VandeHei, CEO of Axios; Marc Boom, M.D., AHA board chair and president and CEO of Houston Methodist; Anne Klibanski, M.D., president and CEO of Mass General Brigham; Jonathan Perlin, M.D., president and CEO of Joint Commission; and Ladd Wiley, senior vice president of global corporate affairs, public policy and advocacy for Epic, all participated in the panel discussion “AI in Health Care: Navigating Policy, Regulation, and the Road Ahead."
Advancing epidemic and pandemic preparedness through research readiness: SEAR Unity Studies Network Sites chart the way forward in 2026
On 25 March 2026, WHO Regional Office for the South‑East Asia Region (SEARO) convened the first meeting of the SEAR Chapter of the Unity Studies Network Meeting in 2026 to take stock of progress and plan next steps for strengthening epidemic and pandemic preparedness across the Region. The meeting focused on reviewing the ongoing adaptation of selected, standard Unity Study methodologies, sharing field implementation experiences from 2025, and identifying key priorities to guide collaborative work in 2026.Held virtually, the meeting brought together representatives from six Unity Studies network sites across five countries (Bangladesh, India, Nepal, Sri Lanka, and Thailand) as well as participants from all three levels of WHO.The meeting took place against the backdrop of ongoing regional efforts in South‑East Asia to strengthen early investigations and studies for epidemic and pandemic preparedness, with a focus on pandemic influenza and other emerging respiratory pathogens with epidemic and pandemic potential. In this context, and as part of preparedness for the rapid generation of evidence, the WHO Health Emergencies Programme in SEAR (WHE/SEAR) encourages Unity Studies sites to adapt prioritized, standardized Unity Study protocols to their national contexts. This approach supports the generation of timely and reliable evidence to inform public health decision‑making during epidemics and pandemics.These efforts are supported through a combination of experience sharing, participation in the global Unity Studies network webinars, capacity‑building of the national public health workforce, and regional collaboration that promotes inter‑country, inter‑agency, and inter‑ministerial action. In parallel, sites are encouraged to explore diversified funding sources to help sustain research preparedness over the long term.Discussions highlighted the importance of WHO’s catalytic financial support through the Pandemic Influenza Preparedness (PIP) Partnership Contributions (PIP‑PC). When combined with national and institutional resources, this support enables countries and sites to maintain continuity of activities at a core level and remain prepared to respond rapidly and effectively to future epidemics and pandemics.Regional and Global Updates: Opening the session, Dr Pushpa Ranjan Wijesinghe, Programme Area Manager, Pandemic and Epidemic Management (PEM) Unit, WHO Health Emergencies Programme, highlighted the progress made in operationalizing the Unity Studies Network across the Region and acknowledged the collaborative efforts of WHO at all three levels, together with country unity studies sites. He emphasized the availability of limited but catalytic funding through the Pandemic Influenza Preparedness (PIP) Partnership Contribution (PIP‑PC) workplan at SEARO to sustain network activities in 2026, while encouraging sites to leverage additional funding sources to expand implementation.Representing SEARO, Dr Ashok Basnet, consultant, Pandemic Influenza Preparedness reported that, at the regional level, the Unity Studies Network currently includes six sites across five countries: Bangladesh, India, Nepal, Sri Lanka, and Thailand. He noted that in 2025, catalytic funding supported protocol adaptation, training, and pilot implementation. In addition, a regional Unity Studies symposium held during the Global Public Health Summit in Sri Lanka strengthened and advocated collaboration between the Unity Studies site, national decision‑making forum, relevant technical units of the ministry of health, WHO and other partners.The symposium also highlighted the role of early investigations and studies as a key component of a multi‑source surveillance system needed at country level to generate a broad range of evidence. It underscored the critical role of country Unity Studies sites and similar research entities in generating evidence to support public health decision‑making during epidemics and pandemics.Participants of the WHO GISRS Unity Studies Sites Network- SEAR Chapter Meeting 2026 (Photo credit- PEM/WHE/SEARO). SEARO also updated participants on ongoing efforts to develop a regional Unity Studies webpage and to promote participation in global knowledge‑sharing platforms, including webinars and the WHO Community of Practice. Priorities for 2026 include supporting the implementation of Unity protocols, strengthening collaboration and experience sharing across sites, documenting and publishing findings, integrating Unity Studies activities as a component of multi-source national surveillance systems, and building workforce capacity.Dr Nickle Boddington of the Global Influenza Programme (GIP) at WHO Headquarters, which coordinates the Unity Studies Network globally, provided updates on global Unity Studies activities, noting that the network has expanded to 16 sites worldwide. New and updated protocols, including rapid clinical severity assessment tools and standardized data platforms, are being developed to support implementation. The global Community of Practice has also been launched to facilitate technical exchange, and continued support will be provided to sites for protocol adaptation, ethical approvals, and readiness for early investigation during outbreaks. Updates from Unity Studies sites in SEAR in 2025Unity Studies sites shared progress and experiences in implementing protocols across diverse country contexts. Sites initiated activities in 2025 using catalytic funding from SEARO, complemented by the mobilization of internal national resources. The Institute of Epidemiology, Disease Control and Research (IEDCR), Bangladesh, reported the adoption and piloting of investigation protocols on non‑seasonal influenza and emerging respiratory diseases during recent avian influenza outbreaks, demonstrating a multi‑source funding approach involving government, WHO and One Health partners.The Hamdard Institute of Medical Sciences and Research (HIMSR), New Delhi, India, highlighted the piloting of household transmission investigation studies, the expansion of the national Unity Studies network, and the contribution of study findings to global evidence through published outputs. The All-India Institute of Medical Sciences (AIIMS), New Delhi, India, shared experiences from large‑scale seroprevalence studies conducted during the COVID‑19 pandemic, recent efforts to strengthen national Unity network sites through training activities, and plans to initiate multi‑centre studies on respiratory viruses.Similarly, Prince of Songkla University, Thailand, highlighted its experience in developing integrated surveillance and diagnostic protocols for multiple respiratory pathogens, enhancing readiness for targeted investigations of emerging threats. The University of Sri Jayewardenepura, Sri Lanka, reported ongoing engagement with the Ministry of Health and exploration of additional funding sources to initiate studies. Meanwhile, the National Public Health Laboratory, Nepal, provided updates on continued coordination with national stakeholders to initiate implementation, despite delays related to the country context.Across sites, shared experiences underscored the importance of protocol adaptation, multisectoral collaboration, and sustainable funding to operationalize Unity Studies and generate evidence for public health action.Discussions and Way ForwardThe meeting reinforced key priorities for 2026, including strengthening unity studies protocol implementation, enhancing collaboration, knowledge sharing, integrating research as a component of national multi-source surveillance systems, and ensuring that generated evidence informs public health decision‑making. Participants also emphasized the importance of documentation, visibility, and leveraging multiple funding sources, and agreed on the following action points.Unity Studies Sites and WHO Country Offices:Advance adoption and implementation of at least one Unity protocol, continuing activities initiated in 2025 with catalytic funding, supplemented with other sources of funding where feasible.Document site-specific experiences, outcomes, and lessons learned; participate in regional and global knowledge-sharing platforms including WHO webinars and the Community of Practice.Work closely with ministries of health to establish unified national platforms for translating generated evidence into national public health decision-making. WHO Country Offices may facilitate technical support and complementary, synergistic funding opportunities where feasible. WHO Regional OfficeCoordinate with WHO Country Offices to support implementation of core unity studies activities by network sites through catalytic funding and provide technical guidance and virtual engagement opportunities throughout 2026.Facilitate the participation of all Unity Studies sites in the regional meeting on Unity Studies implementation in October 2026, to be held back‑to‑back with the Annual SEAR Regional PIP‑PC Meeting; develop and host a SEAR Unity Studies website; and mobilize support from academic institutions within the SEAR Unity Studies Network to support the development of regional manuscripts that showcase Unity Studies activities to scientific audiences and promote knowledge‑sharing.Explore complementary funding opportunities and partnerships to sustain and expand network activities across the Region.WHO HeadquartersProvide global technical guidance, updated protocols, and toolkits to support the implementation of Unity Studies in SEAR.Facilitate engagement of SEAR sites in global webinars, the Community of Practice, and opportunities to showcase their work.Support joint publications, inclusion of SEAR experiences in global outputs, and identification of additional funding and collaborative opportunities to strengthen Unity Studies activities.
UT San Antonio faculty recognized at Shine Academy conference - UT Health San Antonio
Several faculty members from The University of Texas at San Antonio were recognized for excellence and innovation in health science education at the 2026 Kenneth I. Shine, M.D., Academy of Health Science Innovation Annual Conference. The Shine Academy fosters excellence in health sciences education by recognizing outstanding educators and advancing innovation in the field. […]
Baltimore health system leader to receive 2026 AHA Justin Ford Kimball Innovators Award
The AHA today announced that it will present Harsh K. Trivedi, M.D., president and CEO of Sheppard Pratt health system in Baltimore, with the 2026 Justin Ford Kimball Innovators Award during a ceremony April 20 at the AHA Annual Membership Meeting in Washington, D.C.
Brewing Better Health highlights the power of public health partnerships and celebrates National Public Health Week
A Brewing Better Health podcast conversation with Chad Kingsley, M.D., MBA, and Dean Muge Akpinar-Elci, M.D., MPH, on prevention, community health and what public health is.